Husain et al., 2019, in their meta-analysis, assessing the effect of CVOTs of different GLP-1 agonists, including the semaglutide trials SUSTAIN 6 and PIONEER 6, reported a significant reduction in the incidence of non-fatal stroke (HR 0.65 [0.43-0.97]; 95% CI), non-significant reductions in fatal myocardial infarction (HR 0.78 [0.56-1.10]; 95% CI) and non-fatal myocardial infarction (HR 0.88 [0.66-1.18]; 95% CI) [24]. The gene discussed is GCG; the disease is myocardial infarction.